Ophthotech Corp (OPHT) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- US stock futures rise ahead of jobs data; chip, software shares rally
- Oil prices drop as investors weigh potential Hormuz deal between Iran, Gulf states
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Why a solid NFP report could spark a stock selloff, according to JPMorgan
- 'Sell America' trade returns as Fed, yen risks mount
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Nielsen to acquire DoubleVerify in merger deal
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Ophthotech Reports Second Quarter 2015 Financial and Operating Results
August 5, 2015 7:30 AM EDTConference Call and Webcast Today, August 5, 2015, at 8:00 a.m. ET
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the second quarter ended June 30, 2015 and provided an update on the Companys business and product development programs.
Program Highlights
In May 2015, Ophthotech provided updates on the Companys two Phase 3 trials of Fovista® in combination with Lucentis® (ranibizumab) in patients with wet Age-Related Macular Degeneration (AMD). Completion of enrollment of the first Phase 3 trial was announced. In... More
